Literature DB >> 20031857

Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial.

G B John Mancini1, Eric R Bates, David J Maron, Pamela Hartigan, Marcin Dada, Gilbert Gosselin, William Kostuk, Steven P Sedlis, Leslee J Shaw, Daniel S Berman, Peter B Berger, John Spertus, Kreton Mavromatis, Merril Knudtson, Bernard R Chaitman, Robert A O'Rourke, William S Weintraub, Koon Teo, William E Boden.   

Abstract

BACKGROUND: COURAGE compared outcomes in stable coronary patients randomized to optimal medical therapy plus percutaneous coronary intervention (PCI) versus optimal medical therapy alone. METHODS AND
RESULTS: Angiographic data were analyzed by treatment arm, health care system (Veterans Administration, US non-Veterans Administration, Canada), and gender. Veterans Administration patients had higher prevalence of coronary artery bypass graft surgery and left ventricular ejection fraction < or =50%. Men had worse diameter stenosis of the most severe lesion, higher prevalence of prior coronary artery bypass graft surgery, lower left ventricular ejection fraction, and more 3-vessel disease that included a proximal left anterior descending lesion (P<0.0001 for all comparisons versus women). Failure to cross rate (3%) and visual angiographic success of stent procedures (97%) were similar to contemporary practice in the National Cardiovascular Data Registry. Quantitative angiographic PCI success was 93% (residual lesion <50% in-segment) and 82% (<20% in-stent), with only minor nonsignificant differences among health care systems and genders. Event rates were higher in patients with higher jeopardy scores and more severe vessel disease, but rates were similar irrespective of treatment strategy. Within the PCI plus optimal medical therapy arm, complete revascularization was associated with a trend toward lower rate of death or nonfatal myocardial infarction. Complete revascularization was similar between genders and among health care systems.
CONCLUSIONS: PCI success and completeness of revascularization did not differ significantly by health care system or gender and were similar to contemporary practice. Angiographic burden of disease affected overall event rates but not response to an initial strategy of PCI plus optimal medical therapy or optimal medical therapy alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031857     DOI: 10.1161/CIRCOUTCOMES.108.830091

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  12 in total

1.  Does ischemia burden in stable coronary artery disease effectively identify revascularization candidates? Ischemia burden in stable coronary artery disease does not effectively identify revascularization candidates.

Authors:  Harmony R Reynolds; Michael H Picard; Judith S Hochman
Journal:  Circ Cardiovasc Imaging       Date:  2015-05       Impact factor: 7.792

2.  How and when to decide on revascularization in stable ischemic heart disease.

Authors:  Alicia Mecklai; Sripal Bangalore; Judith Hochman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

3.  Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.

Authors:  John A Spertus; David J Maron; David J Cohen; Paul Kolm; Pam Hartigan; William S Weintraub; Daniel S Berman; Koon K Teo; Leslee J Shaw; Steven P Sedlis; Merril Knudtson; Mihaela Aslan; Marcin Dada; William E Boden; G B John Mancini
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-07-09

Review 4.  Revascularization vs. Medical Therapy in Stable Ischemic Heart Disease.

Authors:  Sandra Weiss; William Weintraub
Journal:  Prog Cardiovasc Dis       Date:  2015-07-21       Impact factor: 8.194

5.  Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial.

Authors:  Renato D Lopes; Karen P Alexander; Susanna R Stevens; Harmony R Reynolds; Gregg W Stone; Ileana L Piña; Frank W Rockhold; Ahmed Elghamaz; Jose Luis Lopez-Sendon; Pedro S Farsky; Alexander M Chernyavskiy; Ariel Diaz; Denis Phaneuf; Mark A De Belder; Yi-Tong Ma; Luis A Guzman; Michel Khouri; Alessandro Sionis; Derek J Hausenloy; Rolf Doerr; Joseph B Selvanayagam; Aldo Pietro Maggioni; Judith S Hochman; David J Maron
Journal:  Circulation       Date:  2020-08-29       Impact factor: 29.690

6.  Sex differences in independent factors associated with coronary artery disease.

Authors:  Alois Suessenbacher; Maria Wanitschek; Jakob Dörler; Sabrina Neururer; Matthias Frick; Otmar Pachinger; Hannes F W Alber
Journal:  Wien Klin Wochenschr       Date:  2014-09-13       Impact factor: 1.704

7.  Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease.

Authors:  Steven P Sedlis; Pamela M Hartigan; Koon K Teo; David J Maron; John A Spertus; G B John Mancini; William Kostuk; Bernard R Chaitman; Daniel Berman; Jeffrey D Lorin; Marcin Dada; William S Weintraub; William E Boden
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

8.  A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity.

Authors:  Maha A Al-Mohaissen; Ronald G Carere; G B John Mancini; Karin H Humphries; Beth A Whalen; Terry Lee; Frank X Scheuermeyer; Andrew P Ignaszewski
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 9.  Harmonizing the Paradigm With the Data in Stable Coronary Artery Disease: A Review and Viewpoint.

Authors:  Joshua D Mitchell; David L Brown
Journal:  J Am Heart Assoc       Date:  2017-11-13       Impact factor: 5.501

10.  Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia: Secondary Analysis of the ISCHEMIA Randomized Clinical Trial.

Authors:  Harmony R Reynolds; Leslee J Shaw; James K Min; John A Spertus; Bernard R Chaitman; Daniel S Berman; Michael H Picard; Raymond Y Kwong; C Noel Bairey-Merz; Derek D Cyr; Renato D Lopes; Jose Luis Lopez-Sendon; Claes Held; Hanna Szwed; Roxy Senior; Gilbert Gosselin; Rajesh Gopalan Nair; Ahmed Elghamaz; Olga Bockeria; Jiyan Chen; Alexander M Chernyavskiy; Balram Bhargava; Jonathan D Newman; Sasa B Hinic; Joanna Jaroch; Angela Hoye; Jeffrey Berger; William E Boden; Sean M O'Brien; David J Maron; Judith S Hochman
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.